Poor prognosis acute myelogenous leukemia: 3--biological and molecular biological changes during remission induction therapy.
about
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia.
P2860
Poor prognosis acute myelogenous leukemia: 3--biological and molecular biological changes during remission induction therapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Poor prognosis acute myelogeno ...... g remission induction therapy.
@en
Poor prognosis acute myelogeno ...... g remission induction therapy.
@nl
type
label
Poor prognosis acute myelogeno ...... g remission induction therapy.
@en
Poor prognosis acute myelogeno ...... g remission induction therapy.
@nl
prefLabel
Poor prognosis acute myelogeno ...... g remission induction therapy.
@en
Poor prognosis acute myelogeno ...... g remission induction therapy.
@nl
P2093
P1433
P1476
Poor prognosis acute myelogeno ...... g remission induction therapy.
@en
P2093
Preisler HD
P304
P356
10.1016/S0145-2126(01)00032-7
P577
2001-09-01T00:00:00Z